Welcome to our dedicated page for Tenax Therapeutics news (Ticker: TENX), a resource for investors and traders seeking the latest updates and insights on Tenax Therapeutics stock.
Tenax Therapeutics Inc (TENX) is a clinical-stage pharmaceutical company developing therapies for cardiovascular and pulmonary diseases with high unmet needs. This page provides official updates on clinical trials, regulatory milestones, and corporate developments.
Investors and researchers will find a centralized repository of press releases and verified news related to Tenax's lead candidate levosimendan, including progress on the Phase 3 LEVEL study for PH-HFpEF. Track updates on intellectual property expansions, partnership announcements, and scientific presentations.
All content is curated to meet investor needs for timely, accurate information on drug development progress. Bookmark this page for direct access to primary source materials from Tenax Therapeutics, without promotional commentary or speculative analysis.
Tenax Therapeutics prioritizes the clinical development of TNX-103 (oral levosimendan) for treating pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). This condition affects over 1.6 million North Americans and is expected to exceed 2 million by 2030. The company aims to fill the gap in treatment as there are currently no FDA-approved therapies for PH-HFpEF, with plans to initiate a Phase 3 trial in 2023. The decision to focus on TNX-103 stems from its growing patent estate, potentially providing protection until 2040. A recent patent granted for intravenous levosimendan strengthens its position. Clinical data from the HELP Study supports the drug's efficacy, marking it as a significant advancement in addressing this unmet medical need.
Tenax Therapeutics (Nasdaq: TENX) has secured U.S. Patent No. 11,607,412 for the use of IV levosimendan in treating pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). This patent grants intellectual property protection until December 2040, supporting Tenax's strategy to develop levosimendan, which targets a significant unmet medical need affecting over 1.6 million North Americans. Currently, no FDA-approved treatments exist for PH-HFpEF. Data from the HELP Study indicates that levosimendan significantly improves exercise capacity, further validated by FDA acceptance of the 6-minute walk distance as a Phase 3 endpoint.
Tenax Therapeutics, Inc. (Nasdaq: TENX) announced a public offering of 8,666,666 shares at $1.80 each, alongside warrants for purchasing an additional 17,333,332 shares at an exercise price of $2.25. The offering, expected to close by February 7, 2023, aims to raise approximately $15.6 million in gross proceeds. These funds will support the clinical development of imatinib for pulmonary arterial hypertension (PAH) and levosimendan for pulmonary hypertension with preserved ejection fraction (PH-HFpEF), as well as general corporate purposes. The offering is facilitated by Roth Capital Partners and complies with SEC regulations.
Tenax Therapeutics (Nasdaq: TENX) has been granted a Notice of Allowance for its patent covering the use of IV levosimendan to treat pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF). The patent is expected to provide protection until 2040, enhancing the Company’s intellectual property for levosimendan. This condition affects over 1.5 million patients in the U.S., with no FDA-approved treatments available. The HELP Study has shown levosimendan to significantly improve exercise tolerance in PH-HFpEF patients. This patent underscores the potential of Tenax's therapies to address a critical healthcare need.